期刊
MEDICINAL RESEARCH REVIEWS
卷 33, 期 1, 页码 54-111出版社
WILEY
DOI: 10.1002/med.20245
关键词
5-HT; PET; SPECT; radioligand
资金
- National Institutes of Health
- Lundbeck Foundation
- H. Lundbeck A/S
- Intramural Research Program of the National Institutes of Health (NIMH)
- Medical Research Council [G1002226] Funding Source: researchfish
- NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002793] Funding Source: NIH RePORTER
- MRC [G1002226] Funding Source: UKRI
The serotonergic system plays a key modulatory role in the brain and is the target for many drug treatments for brain disorders either through reuptake blockade or via interactions at the 14 subtypes of 5-HT receptors. This review provides the history and current status of radioligands used for positron emission tomography (PET) and single photon emission computerized tomography (SPECT) imaging of human brain serotonin (5-HT) receptors, the 5-HT transporter (SERT), and 5-HT synthesis rate. Currently available radioligands for in vivo brain imaging of the 5-HT system in humans include antagonists for the 5-HT1A, 5-HT1B, 5-HT2A, and 5-HT4 receptors, and for SERT. Here we describe the evolution of these radioligands, along with the attempts made to develop radioligands for additional serotonergic targets. We describe the properties needed for a radioligand to become successful and the main caveats. The success of a PET or SPECT radioligand can ultimately be assessed by its frequency of use, its utility in humans, and the number of research sites using it relative to its invention date, and so these aspects are also covered. In conclusion, the development of PET and SPECT radioligands to image serotonergic targets is of high interest, and successful evaluation in humans is leading to invaluable insight into normal and abnormal brain function, emphasizing the need for continued development of both SPECT and PET radioligands for human brain imaging. (C) 2011 Wiley Periodicals, Inc. Med Res Rev., 33, No. 1, 54-111, 2013
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据